Date: 2015-07-22
Type of information: Nomination
Compound:
Company: Auspherix (Australia) Auspherix Limited (UK)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 22, 2015, Auspherix Limited has announced that it has expanded and strengthened its Board and Scientific Advisory Board with the appointments of Dr Jared Silverman as Non-Executive Director and Scientific Advisor, and Professor David Livermore as a Scientific Advisor.,Dr Silverman’s career has focused on the discovery and development of novel antibiotics to treat serious, drug resistant infections in the hospital setting. US-based, he is currently VP of Research at VL32, following 18 years at Cubist Pharmaceuticals. He has two decades of experience in converting basic science into clinically and commercially useful data to guide drug development, patient treatment and marketing strategy. His research has contributed to the discovery of three novel antibiotics that entered clinical development. Currently Professor of Medical Microbiology at the University of East Anglia (UEA), he serves on the UK Government’s Antimicrobial Resistance & Healthcare Associated Infection Advisory Committee. Earlier in his career he spent 14 years with the Public Health Laboratory Service (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory, and 17 years at the London Hospital Medical College.Auspherix is actively recruiting to expand its science and management teams.
Financial terms:
Latest news:
